Nat Biotechnol:疫苗添加聚乙烯亚胺可增免疫效果

2012-09-12 黄堃 新华社

一个国际团队的最新研究结果显示,在针对流感等疾病的疫苗中添加一种名为聚乙烯亚胺的物质,可增强疫苗效果,实验鼠如果注射了这种疫苗后,身体可有效对抗大剂量的流感病毒。 疫苗起作用的原理是“训练”免疫系统抗击入侵的病毒和细菌,有些添加剂能增强这种效果,因此许多疫苗都含有被称为“辅助剂”的药品添加剂。英国牛津大学等机构的研究人员在新一期《自然—生物技术》(Nature Biotechnology)杂志上

一个国际团队的最新研究结果显示,在针对流感等疾病的疫苗中添加一种名为聚乙烯亚胺的物质,可增强疫苗效果,实验鼠如果注射了这种疫苗后,身体可有效对抗大剂量的流感病毒。

疫苗起作用的原理是“训练”免疫系统抗击入侵的病毒和细菌,有些添加剂能增强这种效果,因此许多疫苗都含有被称为“辅助剂”的药品添加剂。英国牛津大学等机构的研究人员在新一期《自然—生物技术》(Nature Biotechnology)杂志上发表报告说,聚乙烯亚胺这种添加剂可增强多种疫苗的效果,包括流感疫苗、疱疹疫苗和艾滋病疫苗等。

实验显示,老鼠只需注射一次含有这种添加剂的流感疫苗,接下来即使接触通常情况下会致死的大剂量流感病毒,体内免疫系统仍能有效对抗,效果好于没有添加剂的疫苗,以及使用其他添加剂的疫苗。

研究人员说,接下来将在雪貂身上进行相关实验,雪貂的呼吸系统与老鼠相比更接近人类。

据介绍,聚乙烯亚胺作为疫苗添加剂的另一个优点是可以通过黏膜组织起作用,能够加入那些采用鼻腔吸入方式的疫苗中,使用这些疫苗无需打针,只要深吸一口气即可。由于流感等疾病的病毒也是通过呼吸系统黏膜入侵人体,使用这样的疫苗防治流感也许更有效。

doi:10.1038/nbt.2344
PMC:

PMID:

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens

Frank Wegmann, Kate H Gartlan, Ali M Harandi, Sarah A Brinckmann, Margherita Coccia, William R Hillson, Wai Ling Kok, Suzanne Cole, Ling-Pei Ho, Teresa Lambe, Manoj Puthia, Catharina Svanborg, Erin M Scherer, George Krashias, Adam Williams, Joseph N Blattman, Philip D Greenberg, Richard A Flavell, Amin E Moghaddam, Neil C Sheppard & Quentin J Sattentau 

Protection against mucosally transmitted infections probably requires immunity at the site of pathogen entry1, yet there are no mucosal adjuvant formulations licensed for human use. Polyethyleneimine (PEI) represents a family of organic polycations used as nucleic acid transfection reagents in vitro and DNA vaccine delivery vehicles in vivo2, 3. Here we show that diverse PEI forms have potent mucosal adjuvant activity for viral subunit glycoprotein antigens. A single intranasal administration of influenza hemagglutinin or herpes simplex virus type-2 (HSV-2) glycoprotein D with PEI elicited robust antibody-mediated protection from an otherwise lethal infection, and was superior to existing experimental mucosal adjuvants. PEI formed nanoscale complexes with antigen, which were taken up by antigen-presenting cells in vitro and in vivo, promoted dendritic cell trafficking to draining lymph nodes and induced non-proinflammatory cytokine responses. PEI adjuvanticity required release of host double-stranded DNA that triggered Irf3-dependent signaling. PEI therefore merits further investigation as a mucosal adjuvant for human use.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927593, encodeId=5570192e5930e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sat Jun 22 12:15:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879366, encodeId=e11418e9366eb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 05 14:15:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652072, encodeId=7a8516520e212, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Oct 21 07:15:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054239, encodeId=ced1205423915, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Nov 27 02:15:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916925, encodeId=19451916925ff, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Feb 21 18:15:00 CST 2013, time=2013-02-21, status=1, ipAttribution=)]
    2013-06-22 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927593, encodeId=5570192e5930e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sat Jun 22 12:15:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879366, encodeId=e11418e9366eb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 05 14:15:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652072, encodeId=7a8516520e212, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Oct 21 07:15:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054239, encodeId=ced1205423915, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Nov 27 02:15:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916925, encodeId=19451916925ff, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Feb 21 18:15:00 CST 2013, time=2013-02-21, status=1, ipAttribution=)]
    2013-06-05 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927593, encodeId=5570192e5930e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sat Jun 22 12:15:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879366, encodeId=e11418e9366eb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 05 14:15:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652072, encodeId=7a8516520e212, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Oct 21 07:15:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054239, encodeId=ced1205423915, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Nov 27 02:15:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916925, encodeId=19451916925ff, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Feb 21 18:15:00 CST 2013, time=2013-02-21, status=1, ipAttribution=)]
    2012-10-21 shock_melon
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927593, encodeId=5570192e5930e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sat Jun 22 12:15:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879366, encodeId=e11418e9366eb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 05 14:15:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652072, encodeId=7a8516520e212, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Oct 21 07:15:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054239, encodeId=ced1205423915, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Nov 27 02:15:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916925, encodeId=19451916925ff, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Feb 21 18:15:00 CST 2013, time=2013-02-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927593, encodeId=5570192e5930e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sat Jun 22 12:15:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879366, encodeId=e11418e9366eb, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 05 14:15:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652072, encodeId=7a8516520e212, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Oct 21 07:15:00 CST 2012, time=2012-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054239, encodeId=ced1205423915, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Tue Nov 27 02:15:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916925, encodeId=19451916925ff, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Feb 21 18:15:00 CST 2013, time=2013-02-21, status=1, ipAttribution=)]
    2013-02-21 sunylz

相关资讯

FDA宣布针对2012~13流感季节的疫苗已通过审批

美国食品药品管理局(FDA)宣布,针对2012~13流感季节的疫苗已通过审批。 该疫苗中包含3个病毒株,除了同样包含在2011~2012流感季节疫苗中的甲型/加利福尼亚/7/2009(H1N1)样病毒之外,还纳入了2个新的病毒株:甲型/维多利亚361/2011(H3N2)样病毒和乙型/威斯康辛/1/2010样病毒。 FDA生物制剂评估与研究中心主管Karen Midthun博士在

STM:尼帕病毒和亨德拉病毒治疗性疫苗问世

美国研究人员8月8日在美国《科学—转化医学》杂志上报告说,他们已开发出了针对尼帕病毒和亨德拉病毒的高效疫苗。   尼帕病毒及与其关系紧密的亨德拉病毒均为美国国家卫生研究院研究的罕见病毒,它们能攻击人和动物的肺部和大脑,死亡率分别高达75%和60%,而尼帕病毒还可以人际间传播。   研究人员以亨德拉病毒的表面蛋白——G蛋白为基础,研制出新疫苗,这种疫苗可以激发宿主的免疫反

Sleep:睡眠或影响疫苗疗效

2012年8月6日--一项新的研究表明,睡眠时间较短与乙肝疫苗接种6个月后无临床保护效果之间关联性很大。加利福尼亚大学(UC)罗伯特.伍德.约翰逊基金会(Robert Wood Johnson Foundation )的健康与社会学者Aric A. Prathe普莱瑟博士和其同事在2012年8月份的《睡眠》上报告了他们的发现。普莱瑟博士对《医景医疗新闻》说,“这是我们第一次在实验室外环境下,发现平

2012年全球疫苗市场将有望达到340亿美元

 经济不景气下,往往只有少数行业能够逆流而上。大量数据反映目前诸多行业处于困境下,医疗行业及药品市场仍然保持上升势头。IMS Health公司报告显示:全球药品市场规模将继续扩大,预计未来几年内将增长近3000亿美元,2014年将达到1.1万亿美元。在2010-2014年间,预计全球市场年复合增长率为5-8%,其中传统主要市场,如美国,欧盟和日本的年复合增长率为3-6%,而新兴市场,如中

我国艾滋疫苗进入Ⅱ期临床试验

  8月14日,由国家科技重大专项支持、我国拥有自主知识产权的艾滋病疫苗正式进入Ⅱ期临床试验,首批15名志愿者在北京佑安医院接受了疫苗接种。领衔该重大专项研究的中国疾病预防控制中心邵一鸣研究员称,此次临床试验主要目标是进一步评价该疫苗的安全性和免疫原性,并确定其免疫程序,从而为开展大规模检验疫苗有效性的临床试验作准备。据悉,这是世界上使用复制型活病毒载体研制的艾滋病疫苗首次进入Ⅱ期临床试验。  

Nat Med:新研究显示IMA901肾癌疫苗优于化疗

近日,来自蒂宾根大学等处的研究者发表了两项实验研究结果,揭示了肾癌的疫苗IMA901的部分研究成果,相关研究结果已于近日刊登在了国际著名杂志Nature Medicine上。IMA901常被用来治疗肾癌患者,由10种合成性肿瘤相关多肽(TUMAPs)组成,可以激活机体杀伤T细胞抵御肿瘤的能力。不像化学疗法,以免疫系统为靶点的新疗法可以动员免疫系统来攻击癌症,研究揭示了这种抵御癌症的免疫活性法非常成